STOCK TITAN

DermTech, Inc. - DMTK STOCK NEWS

Welcome to our dedicated page for DermTech news (Ticker: DMTK), a resource for investors and traders seeking the latest updates and insights on DermTech stock.

DermTech, Inc. (symbol: DMTK) is a groundbreaking molecular diagnostic dermatology company dedicated to revolutionizing the diagnosis of skin conditions through innovative non-invasive testing. Located at their CLIA-licensed laboratory in La Jolla, CA, DermTech operates at the cutting edge of dermatological science.

DermTech's core technology focuses on gene expression tests that aid in the clinical diagnosis of skin cancer and other skin conditions. Their flagship product, the Pigmented Lesion Assay (PLA), allows for the analysis of skin biopsy samples using an adhesive patch. This method offers a significant advancement over traditional methods that rely on subjective visual diagnosis and invasive surgical biopsies, which are often prone to error and lead to unnecessary procedures.

The PLA test is designed to detect melanoma in clinically atypical pigmented lesions with high accuracy, providing physicians with critical, objective data to enhance patient care and reduce healthcare costs. By utilizing DermTech’s non-invasive approach, patients experience enhanced comfort and safety during the diagnostic process.

DermTech is committed to advancing the field of dermatology through continuous innovation. In addition to their focus on skin cancer, the company is developing genomic tests to diagnose inflammatory skin diseases and conditions related to aging. These efforts are aimed at providing comprehensive solutions that improve the accuracy of diagnoses and overall patient outcomes.

With a strong emphasis on scientific development and patient care, DermTech partners with various healthcare providers and institutions to expand the availability of their tests. The company generates revenue through their laboratory services, ensuring a sustainable business model while aiming for growth and expanded impact in the dermatology field.

Rhea-AI Summary
DermTech, Inc. (DMTK) reported positive topline results from its Trust 2 Study, demonstrating the powerful clinical utility of the DermTech Melanoma Test (DMT) as a rule-out test for melanoma. The study showed a negative predictive value (NPV) of higher than 99%, reaffirming the DMT's real-world clinical utility and providing actionable genomic information for clinicians and patients. The study also indicated that the DMT may help reduce healthcare costs and support re-engagement with payers for reimbursement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.48%
Tags
-
Rhea-AI Summary
DermTech, Inc. (NASDAQ: DMTK) granted 15 new employees restricted stock units representing the right to receive up to 56,230 shares of the Company’s common stock under its 2022 Inducement Equity Incentive Plan. The units will vest over 4 years, subject to continued employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.39%
Tags
none
-
Rhea-AI Summary
DermTech, Inc. (NASDAQ: DMTK) investors face a December 15, 2023 deadline in a lawsuit over alleged Securities Laws Violations. The lawsuit alleges failure to disclose challenges with collections from commercial payors, leading to lower average selling price and adverse impact on revenue growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.21%
Tags
none
Rhea-AI Summary
DermTech, Inc. reported its third-quarter 2023 financial results, showing a 24% increase in average selling price (ASP) for the DermTech Melanoma Test (DMT) compared to the previous year. Test revenue also increased by 8% compared to the third quarter of 2022. The company's cash runway is expected to extend into the first quarter of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.71%
Tags
-
Rhea-AI Summary
DermTech, Inc. will host a conference call on November 2, 2023, to discuss its third-quarter 2023 operating and financial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.22%
Tags
-
Rhea-AI Summary
DermTech grants equity award to new chief commercial officer, Mark Aguillard
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.94%
Tags
none
Rhea-AI Summary
DermTech announces agreements with Highmark Inc. to enhance access to the DermTech Melanoma Test
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.96%
Tags
none
-
Rhea-AI Summary
DermTech appoints Mark Aguillard as chief commercial officer to focus on generating reimbursed tests and integrating the DermTech Melanoma Test into the melanoma care pathway.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.38%
Tags
management
-
Rhea-AI Summary
DermTech grants restricted stock units to new employees.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.78%
Tags

FAQ

What is the current stock price of DermTech (DMTK)?

The current stock price of DermTech (DMTK) is $0.094 as of June 27, 2024.

What is the market cap of DermTech (DMTK)?

The market cap of DermTech (DMTK) is approximately 3.3M.

What does DermTech, Inc. specialize in?

DermTech specializes in non-invasive molecular diagnostic tests for skin conditions, focusing on skin cancer and other dermatological issues.

How does DermTech's Pigmented Lesion Assay (PLA) work?

The PLA uses an adhesive patch to collect skin biopsy samples non-invasively, providing accurate gene expression analysis for melanoma detection.

Where is DermTech, Inc. located?

DermTech, Inc. is headquartered in La Jolla, CA, where they operate a CLIA-licensed laboratory.

What makes DermTech's diagnostic method unique?

DermTech's method is non-invasive, removing the need for surgical biopsies and providing objective, accurate data for better diagnosis.

What other skin conditions does DermTech focus on?

In addition to skin cancer, DermTech is developing tests for inflammatory skin diseases and aging-related conditions.

How does DermTech improve patient care?

DermTech improves patient care by offering non-invasive, highly accurate diagnostic tests, reducing unnecessary procedures and enhancing comfort.

Is DermTech's technology widely available?

DermTech partners with various healthcare providers and institutions to expand the availability of their innovative diagnostic tests.

How does DermTech generate revenue?

DermTech generates revenue through its laboratory services, offering non-invasive genomic tests to healthcare providers and institutions.

What is DermTech's mission?

DermTech aims to revolutionize dermatological diagnostics through innovative, non-invasive testing methods, improving accuracy and patient outcomes.

What recent achievements has DermTech made?

DermTech continues to innovate in molecular diagnostics, expanding their test offerings and establishing partnerships to enhance their market presence.

DermTech, Inc.

Nasdaq:DMTK

DMTK Rankings

DMTK Stock Data

3.29M
34.96M
2.62%
18.09%
8.64%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
SAN DIEGO